Genmab A (GMAB) EBITDA (2018 - 2026)

Genmab A's EBITDA history runs 6 years deep, the most recent figure standing at $180.0 million for Q1 2026.

• Quarterly EBITDA fell 4.26% year-over-year to $180.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 billion (down 23.66% YoY) and the FY2025 annual result came in at $1.1 billion, up 9.57% from the prior year.
• EBITDA was $180.0 million for Q1 2026 at Genmab A, down from $1.0 billion in the prior quarter.
• Across five years, EBITDA topped out at $1.3 billion in Q4 2024 and bottomed at $116.0 million in Q1 2024.
• A 3-year average of $546.2 million and a median of $450.0 million in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2025 — EBITDA surged 62.07% — and 2026, when it retreated 4.26%.
• Genmab A's EBITDA stood at $1.3 billion in 2024, then fell by 23.54% to $1.0 billion in 2025, then tumbled by 82.13% to $180.0 million in 2026.
• Business Quant data shows GMAB's EBITDA at $180.0 million in Q1 2026, $1.0 billion in Q3 2025, and $548.0 million in Q2 2025.